Natera, Inc. (NTRA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Natera, Inc. (NTRA) Healthcare & Pipeline Overview

Natera, Inc. is a leading diagnostics company focused on developing and commercializing advanced molecular testing services globally. It specializes in non-invasive prenatal, oncology, and organ transplant diagnostics, utilizing proprietary bioinformatics and a broad partner network to deliver crucial genetic insights for patient care and clinical management.

What Is the Investment Thesis for NTRA?

Natera, Inc. presents a compelling case within the diagnostics sector, driven by its innovative portfolio of molecular testing services and strategic market positioning. With a market capitalization of $46.7B and a strong gross margin of 65.2%, the company demonstrates significant operational efficiency in its core business. The investment thesis centers on the expanding adoption of its non-invasive diagnostic platforms, particularly Signatera in oncology and Prospera in organ transplant monitoring, which address large and growing clinical needs. The company's extensive network of over 100 laboratory and distribution partners, coupled with strategic alliances with entities like BGI Genomics and Foundation Medicine, underpins its global commercialization strategy. While Natera currently operates with a profit margin of -9.0%, indicating a focus on growth and R&D investment, the potential for market penetration in high-value segments and the inherent scalability of its cloud-based Constellation software could drive future profitability. The company's high Beta of 1.57 suggests sensitivity to market movements, reflecting its growth-oriented profile within the dynamic healthcare technology landscape. Continued innovation and successful clinical validation of new applications for its core technologies are key value drivers for long-term growth.

Based on FMP financials and quantitative analysis

NTRA Key Highlights

Natera, Inc. commands a substantial market capitalization of $46.7B, reflecting its significant presence in the diagnostics industry.

• The company maintains a robust gross margin of 65.2%, indicating strong profitability from its core molecular testing services.
• Natera operates with a profit margin of -9.0%, demonstrating ongoing investment in research, development, and market expansion.
• With a Beta of 1.57, the stock exhibits higher volatility compared to the broader market, characteristic of a growth-focused healthcare company.
• Natera employs 4,424 individuals, supporting its extensive research, development, sales, and operational functions across its global footprint.

Who Are NTRA's Competitors?

NTRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are NTRA's Key Strengths?

Diverse portfolio of non-invasive molecular diagnostic tests across multiple high-growth clinical areas.

• Strong gross margin of 65.2% indicates efficient cost management for its core services.
• Extensive global commercial reach through a direct sales force and over 100 laboratory/distribution partners.
• Proprietary bioinformatics and cloud-based software (Constellation) offer a technological competitive advantage.
• Strategic partnerships with industry leaders like BGI Genomics and Foundation Medicine enhance R&D and market access.

What Are NTRA's Weaknesses?

Ongoing negative profit margin of -9.0% suggests significant investment in growth or operational inefficiencies.

• High Beta of 1.57 indicates increased stock price volatility, potentially deterring risk-averse investors.
• Reliance on complex molecular technologies requires continuous R&D and intellectual property protection.
• Potential for intense competition from larger, more diversified healthcare companies with greater resources.

What Could Drive NTRA Stock Higher?

NTRA catalyst: Positive clinical trial data or expanded regulatory approvals for Signatera in new cancer indications, potentially broadening its addressable market and clinical utility.

• Increased adoption rates and favorable reimbursement decisions for Prospera, driving greater utilization in organ transplant centers across key markets.
• Expansion of Natera's global laboratory and distribution partner network, facilitating broader access to its molecular testing services in international markets.
• Continued advancements and feature enhancements for the Constellation cloud-based software, attracting more laboratory customers and generating recurring licensing revenue.

What Are the Key Risks for NTRA?

Negative return on equity (-11.7%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $28.2M recently.
• The company's sustained negative profit margin of -9.0% indicates that Natera is currently operating at a loss, which could impact long-term financial stability if profitability is not achieved.
• Intense competition within the diagnostics market, particularly from established players and new entrants, could pressure pricing and market share for Natera's key products.
• Adverse changes in healthcare reimbursement policies or coverage decisions by government and private payers could significantly limit access to Natera's tests and reduce revenue.
• Regulatory hurdles and the lengthy approval processes for new diagnostic tests or expanded indications could delay market entry and commercialization efforts.
• Dependence on the successful development and commercialization of complex molecular technologies carries inherent risks related to research failures, manufacturing challenges, or intellectual property disputes.

What Are the Growth Opportunities for NTRA?

• Growth opportunity 1: Expansion of Signatera in Oncology. The market for circulating tumor DNA (ctDNA) monitoring in oncology is experiencing rapid growth, driven by its potential for early cancer detection, recurrence monitoring, and treatment response assessment. Natera's Signatera technology is uniquely positioned to capitalize on this, offering personalized and highly sensitive ctDNA analysis. Expanding its use into new cancer indications, securing broader reimbursement coverage, and demonstrating improved patient outcomes in clinical trials could significantly increase its market penetration. This market is projected to reach several billion dollars globally within the next five to seven years, representing a substantial long-term opportunity for Natera.
• Growth opportunity 2: Increased Adoption of Prospera in Organ Transplant Monitoring. The demand for non-invasive methods to monitor organ transplant rejection is substantial, as traditional biopsy methods are invasive and carry risks. Prospera, Natera's cell-free DNA test for assessing organ transplant rejection, offers a less invasive and potentially more frequent monitoring solution. Driving increased adoption among transplant centers, securing preferred status in clinical guidelines, and expanding its application to a wider range of transplanted organs could unlock significant revenue streams. The global organ transplant diagnostics market is expected to grow steadily, with Prospera poised to capture a larger share by offering a superior patient and clinician experience.
• Growth opportunity 3: Broadening Penetration of Prenatal Testing Portfolio. Natera's established prenatal testing suite, including Panorama, Vistara, and Horizon, addresses a large and consistently growing market for genetic screening during pregnancy. Opportunities exist to increase market share by expanding geographic reach, securing broader insurance coverage for average-risk pregnancies, and educating healthcare providers on the benefits of comprehensive non-invasive prenatal and carrier screening. The global non-invasive prenatal testing (NIPT) market alone is valued in the billions and is expected to continue its upward trajectory, driven by technological advancements and increased awareness, providing sustained growth for Natera's foundational products.
• Growth opportunity 4: Leveraging Constellation Software Platform. Natera's Constellation cloud-based software provides laboratory customers with access to its proprietary algorithms and bioinformatics, enabling them to validate and launch their own genetic tests. This platform represents a scalable growth opportunity by transforming Natera from solely a service provider to a technology enabler. Expanding the Constellation platform's features, attracting more laboratory partners globally, and potentially offering new bioinformatics tools or test panels could create a recurring revenue stream and solidify Natera's position as a technology leader in genetic diagnostics. This strategy taps into the broader trend of decentralized testing and laboratory empowerment.
• Growth opportunity 5: International Market Expansion through Partnerships. Natera's current network of approximately 100 laboratory and distribution partners provides a solid foundation for international growth. Further expanding this network into underserved or rapidly developing healthcare markets, particularly in Asia, Latin America, and parts of Europe, represents a significant growth driver. Strategic partnerships, such as the one with BGI Genomics Co., Ltd., are crucial for navigating regulatory landscapes and local market dynamics. By adapting its product offerings to regional needs and securing local clinical validations, Natera can tap into new patient populations and healthcare systems, diversifying its revenue base and reducing reliance on any single geographic market.

What Threats Does NTRA Face?

• Rapid technological advancements by competitors could erode Natera's market position or render current tests obsolete.
• Regulatory changes or delays in test approvals could impact market entry or commercialization timelines.
• Reimbursement challenges from payers or changes in healthcare policy could limit access and profitability for tests.
• Intense pricing pressure in the diagnostics market could compress margins despite high gross profitability.
• Data privacy and security concerns associated with genetic information could lead to increased compliance costs or reputational damage.

What Are NTRA's Competitive Advantages?

• Proprietary algorithms and bioinformatics: Natera's cloud-based Constellation platform and advanced analytical capabilities provide a significant technological edge in interpreting complex genetic data.
• Extensive and clinically validated test portfolio: A broad range of non-invasive tests across prenatal, oncology, and transplant diagnostics addresses diverse and critical clinical needs.
• Established global partnership network: Over 100 laboratory and distribution partners, alongside strategic alliances with BGI Genomics and Foundation Medicine, facilitate broad market access and commercialization.
• Direct sales force: A dedicated direct sales team ensures strong relationships with key healthcare providers and accelerates market penetration for specialized diagnostic services.
• Non-invasive technology leadership: Specialization in non-invasive blood-based tests offers patient comfort and safety advantages over traditional invasive procedures, driving adoption.

What Does NTRA Do?

Natera, Inc., founded in 2003 as Gene Security Network, Inc. and rebranded in 2012, is a prominent diagnostics company headquartered in Austin, Texas. The company is dedicated to developing and commercializing a comprehensive suite of molecular testing services that are deployed worldwide. Natera's extensive product portfolio addresses critical areas of healthcare, including prenatal screening, oncology, and organ transplant rejection monitoring. Key offerings include Panorama, a non-invasive prenatal test designed to screen for fetal chromosomal abnormalities, and Vistara, which identifies single-gene disorders. The Horizon carrier screening test determines carrier status for various genetic diseases, while Spectrum assists in identifying chromosomal anomalies or inherited genetic conditions during in vitro fertilization cycles. Beyond reproductive health, Natera offers Anora for miscarriage analysis and non-invasive paternity testing. In the rapidly evolving field of oncology, Signatera stands out as a circulating tumor DNA technology capable of screening for a generic set of mutations independent of an individual's tumor, providing personalized monitoring. Prospera is utilized to assess organ transplant rejection, offering vital information for patient management. The company also provides Constellation, a cloud-based software that grants laboratory customers access to Natera's advanced algorithms and bioinformatics for test validation and launch. Natera distributes its products through a robust direct sales force and an expansive network of approximately 100 laboratory and distribution partners. Strategic partnerships, such as those with BGI Genomics Co., Ltd. for NGS-based genetic testing assays and Foundation Medicine, Inc. for personalized circulating tumor DNA monitoring assays, further enhance its market reach and technological capabilities.

What Products and Services Does NTRA Offer?

• Develops and commercializes molecular testing services globally.
• Offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities.
• Provides Vistara, a single-gene mutation screening test for genetic disorders.
• Conducts Horizon carrier screening for various genetic diseases.
• Supports IVF cycles with Spectrum, identifying chromosomal anomalies or inherited conditions.
• Analyzes causes of miscarriage with Anora miscarriage test products.
• Determines paternity non-invasively using blood draws from pregnant mothers and alleged fathers.
• Offers Signatera, a circulating tumor DNA technology for personalized cancer monitoring.
• Provides Prospera for non-invasive assessment of organ transplant rejection.
• Licenses Constellation, a cloud-based software for laboratory customers to access Natera's bioinformatics.

How Does NTRA Make Money?

• Generates revenue through the sale and commercialization of its molecular diagnostic tests directly to healthcare providers and through a network of laboratory and distribution partners.
• Monetizes its proprietary bioinformatics and algorithms by offering access via the Constellation cloud-based software platform to other laboratories.
• Engages in strategic partnerships, such as with BGI Genomics and Foundation Medicine, to develop, manufacture, and commercialize advanced genetic testing assays.
• Focuses on high-growth segments within prenatal, oncology, and organ transplant diagnostics, leveraging non-invasive technologies for broad market appeal and clinical utility.

What Industry Does NTRA Operate In?

Natera, Inc. operates within the dynamic and rapidly expanding Medical - Diagnostics & Research industry, a critical component of the broader Healthcare sector. The industry is characterized by a strong shift towards non-invasive, personalized, and early detection diagnostics, driven by advancements in genomics, bioinformatics, and molecular biology. Natera is well-positioned within this trend, offering a suite of non-invasive prenatal tests, sophisticated oncology monitoring (circulating tumor DNA), and organ transplant rejection assessment. The competitive landscape is intense, featuring both specialized diagnostics firms and larger diversified healthcare technology companies. Market trends indicate a growing demand for high-accuracy, low-risk diagnostic solutions, particularly those that can integrate with precision medicine approaches. Natera's focus on proprietary algorithms and a broad partner network allows it to compete effectively by offering differentiated and clinically validated services in key high-growth segments of the diagnostics market.

Who Are NTRA's Key Customers?

• Pregnant mothers seeking non-invasive prenatal and carrier screening.
• Healthcare providers including obstetricians, oncologists, and transplant specialists.
• In vitro fertilization (IVF) clinics and fertility specialists.
• Organ transplant recipients requiring rejection monitoring.
• Oncology patients needing personalized circulating tumor DNA monitoring.
• Laboratory and distribution partners utilizing Natera's technology and services globally.

Natera, Inc. Financial Trajectory

Natera, Inc. (NTRA) reported $752.8M in revenue for Q2 FY2026, reflecting 8.1% growth compared to the prior quarter. The company recorded a net loss of $67.0M, with diluted EPS of $-0.47. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, NTRA averaged $-0.34 in diluted EPS.

Company Profile

Natera, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Steven Leonard Chapman. NTRA has traded publicly since 2015.

How Natera, Inc. Is Valued

Natera, Inc. carries a market capitalization of $46.7B, placing it in the large-cap category. Analyst price targets span from $245.00 to $385.00, with a consensus of $323.40. At the current price of $326.14, that implies roughly 1% downside from the consensus target. Relative to its peer group, NTRA's quantitative score of 39/100 is below the peer average of 74/100.

Return on equity for Natera, Inc. stands at -11.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.4%, the inverse of the P/E and a quick read on earnings relative to price.

Natera, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 33.19 places it in the safe zone, indicating low near-term bankruptcy risk.

Natera, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 19.1% above estimates on average.

Over the past six months, Natera, Inc. insiders filed 100 SEC Form 4 transactions — 85 sales and 15 purchases. On net that is roughly 65K shares disposed (about $28.2M), a signal worth weighing alongside the fundamentals.

NTRA Financials

NTRA Latest News

NTRA Analyst Consensus

NTRA MoonshotScore

Natera, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources